These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26885852)

  • 1. Costimulation Engages the Gear in Driving CARs.
    Abken H
    Immunity; 2016 Feb; 44(2):214-6. PubMed ID: 26885852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.
    Kawalekar OU; O'Connor RS; Fraietta JA; Guo L; McGettigan SE; Posey AD; Patel PR; Guedan S; Scholler J; Keith B; Snyder NW; Blair IA; Milone MC; June CH
    Immunity; 2016 Feb; 44(2):380-90. PubMed ID: 26885860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
    Zhong XS; Matsushita M; Plotkin J; Riviere I; Sadelain M
    Mol Ther; 2010 Feb; 18(2):413-20. PubMed ID: 19773745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.
    Cappell KM; Kochenderfer JN
    Nat Rev Clin Oncol; 2021 Nov; 18(11):715-727. PubMed ID: 34230645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors.
    Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
    Sci Rep; 2019 Jul; 9(1):10862. PubMed ID: 31350431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curtailed T-cell activation curbs effector differentiation and generates CD8
    Zanon V; Pilipow K; Scamardella E; De Paoli F; De Simone G; Price DA; Martinez Usatorre A; Romero P; Mavilio D; Roberto A; Lugli E
    Eur J Immunol; 2017 Sep; 47(9):1468-1476. PubMed ID: 28671275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.
    Alvarez-Fernández C; Escribà-Garcia L; Vidal S; Sierra J; Briones J
    J Transl Med; 2016 Jul; 14(1):214. PubMed ID: 27435312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
    Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
    Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks.
    Jaeger-Ruckstuhl CA; Lo Y; Fulton E; Waltner OG; Shabaneh TB; Simon S; Muthuraman PV; Correnti CE; Newsom OJ; Engstrom IA; Kanaan SB; Bhise SS; Peralta JMC; Ruff R; Price JP; Stull SM; Stevens AR; Bugos G; Kluesner MG; Voillet V; Muhunthan V; Morrish F; Olson JM; Gottardo R; Sarthy JF; Henikoff S; Sullivan LB; Furlan SN; Riddell SR
    Immunity; 2024 Feb; 57(2):287-302.e12. PubMed ID: 38354704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifting the Evolving CAR T Cell Platform into Higher Gear.
    Holohan DR; Lee JC; Bluestone JA
    Cancer Cell; 2015 Oct; 28(4):401-402. PubMed ID: 26461084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
    Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ
    J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bumpy Road to CAR Activation.
    Janelle V
    Mol Ther; 2019 Jan; 27(1):14-16. PubMed ID: 30553566
    [No Abstract]   [Full Text] [Related]  

  • 13. CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells.
    Velasquez MP; Szoor A; Vaidya A; Thakkar A; Nguyen P; Wu MF; Liu H; Gottschalk S
    Cancer Immunol Res; 2017 Oct; 5(10):860-870. PubMed ID: 28821531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrupting CD28 costimulation before antigen rechallenge affects CD8(+) T-cell expansion and effector functions during secondary response in mice.
    Fröhlich M; Gogishvili T; Langenhorst D; Lühder F; Hünig T
    Eur J Immunol; 2016 Jul; 46(7):1644-55. PubMed ID: 27122236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
    Ramachandran M; Dimberg A; Essand M
    Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.
    McKee SJ; Doff BL; Soon MS; Mattarollo SR
    Cancer Immunol Res; 2017 Mar; 5(3):191-197. PubMed ID: 28115358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
    Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
    J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Consequences of T-cell Costimulation in Anticancer Immunity.
    Teijeira A; Garasa S; Etxeberria I; Gato-Cañas M; Melero I; Delgoffe GM
    Cancer Immunol Res; 2019 Oct; 7(10):1564-1569. PubMed ID: 31575551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.